Profile data is unavailable for this security.
About the company
CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. It has studied leronlimab in multiple therapeutic areas, including infectious disease, oncology, and autoimmune conditions. The Company has conducted clinical trials of leronlimab as a viral entry inhibitor for human immunodeficiency virus (HIV), believed to competitively bind to the N-terminus and second extracellular loop of the CCR5 receptor. For immunology, the CCR5 receptor is believed to be implicated in immune-mediated illnesses such as Metabolic dysfunction-associated steatohepatitis. It has a joint development agreement with a third-party generative artificial intelligence (AI) drug discovery and development company to develop one or more longer-acting molecules.
- Revenue in USD (TTM)0.00
- Net income in USD-20.53m
- Incorporated2018
- Employees9.00
- LocationCytodyn Inc1111 Main St Ste 660VANCOUVER 98660-2970United StatesUSA
- Phone+1 (360) 980-8524
- Fax+1 (302) 655-5049
- Websitehttps://www.cytodyn.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiff Oncology Inc | 689.00k | -43.01m | 129.37m | 31.00 | -- | 2.50 | -- | 187.76 | -0.9493 | -0.9493 | 0.0152 | 1.01 | 0.0091 | -- | 1.69 | 22,225.81 | -56.80 | -31.24 | -66.22 | -33.56 | -- | -- | -6,238.17 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Skye Bioscience Inc | 0.00 | -21.24m | 129.85m | 11.00 | -- | 1.71 | -- | -- | -0.8405 | -0.8405 | 0.00 | 2.50 | 0.00 | -- | -- | 0.00 | -43.73 | -232.67 | -54.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
| Inhibikase Therapeutics Inc | 0.00 | -19.57m | 133.04m | 8.00 | -- | -- | -- | -- | -2.72 | -2.72 | 0.00 | -0.0711 | 0.00 | -- | -- | 0.00 | -175.81 | -66.49 | -267.87 | -85.55 | -- | -- | -- | -1,139.14 | -- | -- | -- | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
| Black Diamond Therapeutics Inc | 0.00 | -73.10m | 137.50m | 54.00 | -- | 1.41 | -- | -- | -1.36 | -1.36 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -47.12 | -40.29 | -53.28 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
| Vaxart Inc | 16.76m | -72.34m | 138.24m | 109.00 | -- | 2.02 | -- | 8.25 | -0.4182 | -0.4182 | 0.0928 | 0.3009 | 0.1231 | -- | 8.18 | 153,761.50 | -53.13 | -49.60 | -80.07 | -54.86 | -- | -- | -431.61 | -1,398.00 | -- | -189.18 | 0.0665 | -- | 6,796.26 | 12.15 | 23.47 | -- | 21.49 | -- |
| TuHURA Biosciences Inc | 0.00 | -8.50m | 138.28m | 1.00 | -- | -- | -- | -- | -75.24 | -75.24 | 0.00 | 2.38 | 0.00 | -- | -- | 0.00 | -163.44 | -224.08 | -343.80 | -346.74 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.40 | -- | -- | -- |
| Seres Therapeutics Inc | 64.00k | -165.29m | 138.53m | 233.00 | -- | 5.79 | -- | 2,164.47 | -1.14 | -0.2271 | 0.0004 | 0.1405 | 0.0002 | -- | -- | 274.68 | -60.50 | -41.51 | -82.15 | -54.13 | -- | -- | -258,259.40 | -170.14 | -- | -20.45 | 0.00 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| CytoDyn Inc | 0.00 | -20.53m | 141.87m | 9.00 | -- | -- | -- | -- | -0.0241 | -0.0241 | 0.00 | -0.0699 | 0.00 | -- | -- | 0.00 | -94.20 | -259.15 | -- | -- | -- | -- | -- | -232,918.20 | -- | 1.36 | -- | -- | -- | -- | 35.70 | -- | -- | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -81.67m | 142.39m | 51.00 | -- | 0.6556 | -- | -- | -1.37 | -1.37 | 0.00 | 3.62 | 0.00 | -- | -- | 0.00 | -29.52 | -- | -30.98 | -- | -- | -- | -- | -- | -- | -- | 0.1202 | -- | -- | -- | -22.20 | -- | -- | -- |
| PepGen Inc | 0.00 | -87.23m | 143.42m | 64.00 | -- | 1.04 | -- | -- | -2.98 | -2.98 | 0.00 | 4.22 | 0.00 | -- | -- | 0.00 | -52.16 | -- | -58.79 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Sagimet Biosciences Inc | 0.00 | -37.52m | 145.52m | 10.00 | -- | 0.8526 | -- | -- | -1.29 | -1.29 | 0.00 | 5.30 | 0.00 | -- | -- | 0.00 | -27.02 | -- | -27.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
| Achieve Life Sciences Inc | 0.00 | -32.94m | 147.84m | 22.00 | -- | 4.72 | -- | -- | -1.13 | -1.13 | 0.00 | 0.9124 | 0.00 | -- | -- | 0.00 | -91.19 | -86.31 | -107.21 | -119.59 | -- | -- | -- | -- | -- | -22.54 | 0.2384 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
| Atossa Therapeutics Inc | 0.00 | -26.91m | 150.91m | 10.00 | -- | 2.05 | -- | -- | -0.2144 | -0.2144 | 0.00 | 0.5857 | 0.00 | -- | -- | 0.00 | -29.71 | -29.97 | -31.30 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
| Instil Bio Inc | 0.00 | -75.17m | 151.93m | 49.00 | -- | 0.8645 | -- | -- | -11.56 | -11.56 | 0.00 | 27.02 | 0.00 | -- | -- | 0.00 | -24.53 | -- | -25.52 | -- | -- | -- | -- | -- | -- | -492.20 | 0.3179 | -- | -- | -- | 30.06 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Eagle Bay Advisors LLCas of 30 Sep 2024 | 162.11k | 0.01% |
| Diversified Trust Co.as of 30 Sep 2024 | 45.79k | 0.00% |
| Williams Jones Wealth Management LLCas of 30 Sep 2024 | 45.00k | 0.00% |
| Virtue Capital Management LLCas of 30 Jun 2024 | 45.00k | 0.00% |
| RFP Financial Group LLCas of 30 Sep 2024 | 41.45k | 0.00% |
| Next Capital Management LLCas of 30 Sep 2024 | 32.50k | 0.00% |
| Horizon Financial Services LLCas of 30 Sep 2024 | 18.20k | 0.00% |
| Ancora Family Wealth Advisors LLCas of 30 Sep 2024 | 9.49k | 0.00% |
| CAZ Investments LPas of 30 Sep 2024 | 4.00k | 0.00% |
| Willis Investment Counsel, Inc.as of 30 Sep 2024 | 0.00 | 0.00% |
